Cargando…

Myosin Heavy Chain Converter Domain Mutations Drive Early-Stage Changes in Extracellular Matrix Dynamics in Hypertrophic Cardiomyopathy

More than 60% of hypertrophic cardiomyopathy (HCM)-causing mutations are found in the gene loci encoding cardiac myosin-associated proteins including myosin heavy chain (MHC) and myosin binding protein C (MyBP-C). Moreover, patients with more than one independent HCM mutation may be at increased ris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsieh, Jeanne, Becklin, Kelsie L., Givens, Sophie, Komosa, Elizabeth R., Lloréns, Juan E. Abrahante, Kamdar, Forum, Moriarity, Branden S., Webber, Beau R., Singh, Bhairab N., Ogle, Brenda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245526/ https://www.ncbi.nlm.nih.gov/pubmed/35784482 http://dx.doi.org/10.3389/fcell.2022.894635

Ejemplares similares

254 A systems genomics approach to identify novel drug targets of Ewing sarcoma through ancestry-informed human iPSC modeling
por: Moss, Rachel M, et al.
Publicado: (2023)

454 A Human 3D Model of Duchenne Muscular Dystrophy Cardiomyopathy to Investigate Calcium Regulation and Mitochondrial Dysfunction
por: Ernst, Patrick, et al.
Publicado: (2023)

Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy
por: Kawana, Masataka, et al.
Publicado: (2017)

Moderating the Myosin Motor to Treat Hypertrophic Cardiomyopathy
por: Papp, Zoltán
Publicado: (2022)

EditR: A Method to Quantify Base Editing from Sanger Sequencing
por: Kluesner, Mitchell G., et al.
Publicado: (2018)

Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy
por: Foglieni, Chiara, et al.
Publicado: (2022)

The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy
por: Jacques, Adam M., et al.
Publicado: (2008)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

Misclassification of hypertrophic cardiomyopathy: validation of diagnostic codes
por: Magnusson, Peter, et al.
Publicado: (2017)

Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light
por: Trivedi, Darshan V., et al.
Publicado: (2017)

Getting inside the engine - myosin modulation in hypertrophic cardiomyopathy and systolic heart failure
por: Daniels, Matthew J, et al.
Publicado: (2021)

Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease
por: Johnson, Matthew J., et al.
Publicado: (2018)

The Influence of Angiotensin Converting Enzyme and Angiotensinogen Gene Polymorphisms on Hypertrophic Cardiomyopathy
por: Luo, Rong, et al.
Publicado: (2013)

The Hypertrophic Cardiomyopathy Myosin Mutation R453C Alters ATP Binding and Hydrolysis of Human Cardiac β-Myosin
por: Bloemink, Marieke, et al.
Publicado: (2014)

A rare case report of severe cardiomyopathy associated with myotonic dystrophy type 2
por: Touma, Anja M, et al.
Publicado: (2022)

Unequal allelic expression of wild-type and mutated β-myosin in familial hypertrophic cardiomyopathy
por: Tripathi, Snigdha, et al.
Publicado: (2011)

Myosin Modulators: The New Era of Medical Therapy for Systolic Heart Failure and Hypertrophic Cardiomyopathy
por: Lekaditi, Dimitra, et al.
Publicado: (2021)

Impact of Angiotensin I Converting Enzyme Insertion/Deletion Polymorphisms on Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy Risk
por: Yang, Jianmin, et al.
Publicado: (2013)

Mutations in myosin S2 alter cardiac myosin-binding protein-C interaction in hypertrophic cardiomyopathy in a phosphorylation-dependent manner
por: Singh, Rohit R., et al.
Publicado: (2021)

Mutation Analysis of Three Exons of Myosin-Binding Protein C3 in Patients with Hypertrophic Cardiomyopathy
por: Mobasheri, Maryam Beigom, et al.
Publicado: (2016)

β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity
por: Adhikari, Arjun S., et al.
Publicado: (2019)

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition
por: Robert-Paganin, Julien, et al.
Publicado: (2018)

Myosin-binding Protein C Compound Heterozygous Variant Effect on the Phenotypic Expression of Hypertrophic Cardiomyopathy
por: Rafael, Julianny Freitas, et al.
Publicado: (2017)

Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes
por: Alamo, Lorenzo, et al.
Publicado: (2017)

Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers
por: Adalsteinsdottir, Berglind, et al.
Publicado: (2020)

Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy
por: Toepfer, Christopher N., et al.
Publicado: (2020)

Unexpectedly Low Mutation Rates in Beta-Myosin Heavy Chain and Cardiac Myosin Binding Protein Genes in Italian Patients With Hypertrophic Cardiomyopathy
por: Roncarati, Roberta, et al.
Publicado: (2011)

The R403Q Myosin Mutation Implicated in Familial Hypertrophic Cardiomyopathy Causes Disorder at the Actomyosin Interface
por: Volkmann, Niels, et al.
Publicado: (2007)

Screening mutations in myosin binding protein C3 gene in a cohort of patients with Hypertrophic Cardiomyopathy
por: Rodríguez-García, María Isabel, et al.
Publicado: (2010)

Prevalence of cardiac myosin-binding protein C3 mutations in Maine Coon cats with hypertrophic cardiomyopathy
por: Sukumolanan, Pratch, et al.
Publicado: (2022)

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
por: Masri, Ahmad, et al.
Publicado: (2022)

Hypertrophic cardiomyopathy
por: Antunes, Murillo de Oliveira, et al.
Publicado: (2020)

Hypertrophic Cardiomyopathy
por: Butt, Asra K., et al.
Publicado: (2023)

Hypertrophic cardiomyopathy mutations in the pliant and light chain-binding regions of the lever arm of human β-cardiac myosin have divergent effects on myosin function
por: Morck, Makenna M, et al.
Publicado: (2022)

A Novel Myosin Essential Light Chain Mutation Causes Hypertrophic Cardiomyopathy with Late Onset and Low Expressivity
por: Andersen, Paal Skytt, et al.
Publicado: (2012)

Prolonged cross-bridge binding triggers muscle dysfunction in a Drosophila model of myosin-based hypertrophic cardiomyopathy
por: Kronert, William A, et al.
Publicado: (2018)

Hypertrophic cardiomyopathy in purpose-bred cats with the A31P mutation in cardiac myosin binding protein-C
por: Stern, Joshua A., et al.
Publicado: (2023)

Prospects for remodeling the hypertrophic heart with myosin modulators
por: Sewanan, Lorenzo R., et al.
Publicado: (2022)

Genetic polymorphism of angiotensin-converting enzyme and hypertrophic cardiomyopathy risk: A systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2017)

The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy
por: Kittleson, Mark D, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_91me3jk3r826i469119uvrfe69